REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin 2018;69:7-34.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.

3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7-33.

4. Fizazi K, Shore N, Tammela TL, et al. ARAMIS Investigators. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380:1235-46.

5. Zhang W, van Gent DC, Incrocci L, van Weerden WM, Nonnekens J. Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer Prostatic Dis 2020;23:24-37.

6. Banks P, Xu W, Murphy D, James P, Sandhu S. Relevance of DNA damage repair in the management of prostate cancer. Curr Probl Cancer 2017;41:287-301.

7. Goodwin JF, Schiewer MJ, Dean JL, et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 2013;3:1254-71.

8. Li L, Karanika S, Yang G, et al. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 2017;10:eaam7479.

9. Polkinghorn WR, Parker JS, Lee MX, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013;3:1245-53.

10. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 2015;4:365-80.

11. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008;15:841-9.

12. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.

13. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:12-23.

14. Silljé HH, Takahashi K, Tanaka K, Van Houwe G, Nigg EA. Mammalian homologues of the plant tousled gene code for cell-cycle-regulated kinases with maximal activities linked to ongoing DNA replication. EMBO J 1999;18:5691-702.

15. De Benedetti A. The tousled-like kinases as guardians of genome integrity. ISRN Mol Biol 2012;2012:627596.

16. Segura-Bayona S, Stracker TH. The tousled-like kinases regulate genome and epigenome stability: implications in development and disease. Cell Mol Life Sci 2019;76:3827-41.

17. Sunavala-Dossabhoy G. Preserving salivary gland physiology against genotoxic damage - the tousled way. Oral Dis 2018;24:1390-8.

18. Li Y, DeFatta R, Anthony C, Sunavala G, De Benedetti A. A translationally regulated tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 2001;20:726-38.

19. Mortuza GB, Hermida D, Pedersen AK, et al. Molecular basis of tousled-Like Kinase 2 activation. Nat Commun 2018;9:2535.

20. Sunavala-Dossabhoy G, Fowler M, De Benedetti A. Translation of the radioresistance kinase TLK1B is induced by gamma-irradiation through activation of mTOR and phosphorylation of 4E-BP1. BMC Mol Biol 2004;5:1.

21. Norton KS, McClusky D, Sen S, et al. TLK1B is elevated with eIF4E overexpression in breast cancer. J Surg Res 2004;116:98-103.

22. Sunavala-Dossabhoy G, Li Y, Williams B, De Benedetti A. A dominant negative mutant of TLK1 causes chromosome missegregation and aneuploidy in normal breast epithelial cells. BMC Cell Biol 2003;4:16.

23. Klimovskaia IM, Young C, Strømme CB, et al. Tousled-like kinases phosphorylate Asf1 to promote histone supply during DNA replication. Nat Commun 2014;5:3394.

24. Sunavala-Dossabhoy G, Balakrishnan SK, Sen S, Nuthalapaty S, De Benedetti A. The radioresistance kinase TLK1B protects the cells by promoting repair of double strand breaks. BMC Mol Biol 2005;6:19.

25. Sunavala-Dossabhoy G, De Benedetti A. Tousled homolog, TLK1, binds and phosphorylates Rad9; TLK1 acts as a molecular chaperone in DNA repair. DNA Repair (Amst) 2009;8:87-102.

26. Awate S, De Benedetti A. TLK1B mediated phosphorylation of Rad9 regulates its nuclear/cytoplasmic localization and cell cycle checkpoint. BMC Mol Biol 2016;17:3.

27. Singh V, Connelly ZM, Shen X, De Benedetti A. Identification of the proteome complement of humanTLK1 reveals it binds and phosphorylates NEK1 regulating its activity. Cell Cycle 2017;16:915-26.

28. Jiang J, Jia P, Zhao Z, Shen B. Key regulators in prostate cancer identified by co-expression module analysis. BMC Genomics 2014;15:1015.

29. Khalil MI, Singh V, King J, De Benedetti A. TLK1-MK5 axis drives prostate cancer cell motility and pathologic features of aggressiveness. Res Sq 2021; doi: 10.21203/rs.3.rs-434116/v1.

30. Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors. Int J Cancer 2019;145:1055-67.

31. Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. The TLK1-Nek1 axis promotes prostate cancer progression. Cancer Lett 2019;453:131-41.

32. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19:575-86.

33. Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011;19:792-804.

34. Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009;16:259-66.

35. Magee JA, Chang LW, Stormo GD, Milbrandt J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 2006;147:590-8.

36. Hausch F, Kozany C, Theodoropoulou M, Fabian AK. FKBPs and the Akt/mTOR pathway. Cell Cycle 2013;12:2366-70.

37. Polci R, Peng A, Chen PL, Riley DJ, Chen Y. NIMA-related protein kinase 1 is involved early in the ionizing radiation-induced DNA damage response. Cancer Res 2004;64:8800-3.

38. Chen Y, Chen PL, Chen CF, Jiang X, Riley DJ. Never-in-mitosis related kinase 1 functions in DNA damage response and checkpoint control. Cell Cycle 2008;7:3194-201.

39. Liu S, Ho CK, Ouyang J, Zou L. Nek1 kinase associates with ATR-ATRIP and primes ATR for efficient DNA damage signaling. Proc Natl Acad Sci U S A 2013;110:2175-80.

40. Al-Ubaidi FL, Schultz N, Loseva O, Egevad L, Granfors T, Helleday T. Castration therapy results in decreased Ku70 levels in prostate cancer. Clin Cancer Res 2013;19:1547-56.

41. Teyssonneau D, Margot H, Cabart M, et al. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol 2021;14:51.

42. Karanika S, Karantanos T, Li L, et al. Targeting DNA damage response in prostate cancer by inhibiting androgen receptor-CDC6-ATR-Chk1 signaling. Cell Rep 2017;18:1970-81.

43. Karanika S, Karantanos T, Li L, Corn PG, Thompson TC. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 2015;34:2815-22.

44. Ronald S, Awate S, Rath A, et al. Phenothiazine inhibitors of TLKs affect double-strand break repair and DNA damage response recovery and potentiate tumor killing with radiomimetic therapy. Genes Cancer 2013;4:39-53.

45. Jin X, Zou B, Luo L, et al. Codelivery of thioridazine and doxorubicin using nanoparticles for effective breast cancer therapy. Int J Nanomedicine 2016;11:4545-52.

46. Ibrahim K, Abdul Murad NA, Harun R, Jamal R. Knockdown of tousled-like kinase 1 inhibits survival of glioblastoma multiforme cells. Int J Mol Med 2020;46:685-99.

47. Takayama Y, Kokuryo T, Yokoyama Y, et al. Silencing of tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis. Cancer Lett 2010;296:27-34.

48. Rho SB, Kim BR, Kang S. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol 2011;120:121-7.

49. Nomura T, Mimata H. . Molecular mechanisms of cisplatin resistance in prostate cancer cells. In: Parsons RA, editor. Progress in Cancer Drug Resistance Research. NOVA; 2007; p. 121.

50. Shu Y, Xie B, Liang Z, Chen J. Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met. Oncol Lett 2018;15:2252-8.

51. Singh V, Bhoir S, Chikhale RV, et al. Generation of phenothiazine with potent anti-TLK1 activity for prostate cancer therapy. iScience 2020;23:101474.

52. Khalil MI, Ghosh I, Singh V, Chen J, Zhu H, De Benedetti A. NEK1 Phosphorylation of YAP promotes its stabilization and transcriptional output. Cancers (Basel) 2020;12:3666.

53. Yim H, Sung CK, You J, Tian Y, Benjamin T. Nek1 and TAZ interact to maintain normal levels of polycystin 2. J Am Soc Nephrol 2011;22:832-7.

54. Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B. YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun 2015;6:8126.

55. Salem O, Hansen CG. The hippo pathway in prostate cancer. Cells 2019;8:370.

56. Singh V, Khalil MI, De Benedetti A. The TLK1/Nek1 axis contributes to mitochondrial integrity and apoptosis prevention via phosphorylation of VDAC1. Cell Cycle 2020;19:363-75.

57. Shoshan-Barmatz V, Golan M. Mitochondrial VDAC1: function in cell life and death and a target for cancer therapy. Curr Med Chem 2012;19:714-35.

58. Chen Y, Craigen WJ, Riley DJ. Nek1 regulates cell death and mitochondrial membrane permeability through phosphorylation of VDAC1. Cell Cycle 2009;8:257-67.

59. Khalil MI, Madere C, Ghosh I, Adam RM, De Benedetti A. Interaction of TLK1 and AKTIP as a potential regulator of AKT activation in castration-resistant prostate cancer progression. Pathophysiology 2021;28:339-54.